Loading...
Market
Will Liraglutide (Victoza) enter Phase 3 clinical trials for Alzheimer's by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from Novo Nordisk or clinical trial registries
Story
Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression
Jul 30, 2024, 11:14 AM
Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Not started • 25%
Yes • 50%
No • 50%
